Coraxan Use in Patients with Cardiovascular and Pulmonary Pathology

dc.contributor.author	Rajabova N.T
dc.contributor.author	Kilicheva T.A
dc.date.accessioned	2025-12-29T08:05:39Z
dc.date.issued	2024-01-30
dc.description.abstract	The article studies the efficacy of the drug Coraxan in the complex therapy of patients with coronary heart disease (CHD) and arterial hypertension (AH) in combination with chronic obstructive pulmonary disease (COPD). The use of Coraxan in the treatment of patients with combined cardiopulmonary pathology leads to a significant decrease in blood pressure (BP) and heart rate (HR), reduction of angina attacks. Coraxan increases tolerance to physical activity (PA).
dc.format	application/pdf
dc.identifier.uri	https://peerianjournal.com/index.php/tpj/article/view/744
dc.identifier.uri	https://asianeducationindex.com/handle/123456789/14491
dc.language.iso	eng
dc.publisher	Peerian Journals Publishing
dc.relation	https://peerianjournal.com/index.php/tpj/article/view/744/620
dc.rights	https://creativecommons.org/licenses/by/4.0
dc.source	The Peerian Journal; Vol. 26 (2024): TPJ; 25-28
dc.source	2788-0303
dc.subject	Coraxan
dc.subject	ischemic heart disease
dc.subject	blood pressure
dc.title	Coraxan Use in Patients with Cardiovascular and Pulmonary Pathology
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion
dc.type	Peer-reviewed Article

item.page.files

pagination.showing.labelpagination.showing.detail

item.page.filesection.name: nt_2024_coraxan_use_in_patients_with_cardiovascu.pdf
item.page.filesection.size: 221.97 KB
item.page.filesection.format: Adobe Portable Document Format